VPRIV (velaglucerase alfa) for injection
Vpriv is used for the long-term treatment of patients with Gaucher disease. Gaucher disease is a rare inherited disorder, in which people do not have enough of an enzyme called glucocerebrosidase, which normally breaks down a fat called glucocerebroside. VPRIV (velaglucerase alfa for injection) Initial U.S. Approval: 2010
Home | velaglucerase alfa for injection
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
VPRIV (velaglucerase alfa for injection)
Velaglucerase alfa injection is used to treat type 1 Gaucher's disease. This disease is caused by the lack of a certain enzyme, glucocerebrosidase, in the body. This enzyme is necessary for the body to use fats correctly, and fats will build up in certain areas of the body if the enzyme is not present.
VPRIV (velaglucerase alfa for injection) is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease
Velaglucerase alfa, sold under the brand name Vpriv, is a medication used for the treatment of Gaucher disease Type 1. It is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase. It has an identical amino acid sequence to the naturally occurring enzyme. Velaglucerase alfa was approved for medical use in the United States in February 2010, and in the European Union in August 2010.
Drug (Brand / Generic): VPRIV /velaglucerase alfa
Current Indication: treat patients with Gaucher disease
Approval Date: Aug 1, 2010
Shire Human Genetic Therapies, Inc.
• Lyophilized powder to be reconstituted and diluted for infusion.
• Available in 200 Units and 400 Units single-use vials.
VPRIV is a sterile, preservative free, lyophilized powder requiring reconstitution and further dilution prior to use. It is supplied in individually packaged glass vials, which are closed with a butyl rubber stopper with a fluoro-resin coating and are sealed with an aluminum overseal with a flip-off plastic cap. The vials are intended for single use only. VPRIV is available as: 200 Units/vial NDC 54092-701-02 and 400 Units/vial NDC 54092-701-04
Find Reference Updates
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ VPRIV (velaglucerase alfa) for injection ”. Confirmation of the order for VPRIV (velaglucerase alfa) for injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – VPRIV
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha.